Article snapshot taken from Wikipedia with creative commons attribution-sharealike license.
Give it a read and then ask your questions in the chat.
We can research this topic together.
This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 23:08, 13 November 2011 (Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report ...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA).
Another phase III trial for hip pain in OA was halted in June 2010 when some patients needed hip replacement.
Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.
Robert J. Evans III, MD is board certified, a fellow in the American College of Surgeons, and is currently the principal investigator in the clinical trial evaluating the new drug tanezumab for treating interstitial cystitis. A specialist in painful bladder syndrome, Dr. Evans is a member of the medical advisory board of the Interstitial Cystitis Association and practices medicine with the department of urology at Wake Forest University Baptist Medical Center, Winston-Salem, NC.
